Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kala Pharmaceuticals Inc

Why Kala Pharmaceuticals Shares Are Rising Today

Kala Pharmaceuticals Inc (NASDAQ: KALA) shares are trading higher after the company said it would sell its EYSUVIS and INVELTYS treatments for $60 million.

Benzinga · May 23, 2022

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

Kala Pharmaceuticals Inc (NASDAQ:KALA) reported data from a Phase 1b trial of KPI-012, a cell-free secretome therapy for severe ocular diseases driven by impaired healing. As previously disclosed, KPI-012 was well tolerated and resulted in significant improvements in various persistent corneal epithelial defect (PCED) etiologies. The data will be presented at the 2022…

Benzinga · May 2, 2022

This Microcap Pharma Stock Almost Doubled Today - Read Why

This Microcap Pharma Stock Almost Doubled Today - Read Why

UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ:KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022. Eysuvis now has coverage for approximately 118 million lives or 70% of all commercial lives. Kala also announced that Cigna Medicare had added Eysuvis as a preferred brand effective…

Benzinga · Mar 8, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Benzinga

Organisations

UnitedHealthcare

Express Scripts

Kala Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play